Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Dr. Secord on Personalized Treatment in Ovarian Cancer

September 15th 2018

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses the growing potential for personalized treatment in ovarian cancer.

Dr. Powell Discusses Data With Immunotherapy in Ovarian Cancer

September 8th 2018

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses data with immunotherapy in ovarian cancer.

PARP/Immunotherapy Combo Shows Promise in Recurrent Ovarian Cancer

September 5th 2018

Panagiotis A. Konstantinopoulos, MD, PhD, discusses the findings of the TOPACIO/KEYNOTE-162 study and the future for PARP inhibitor combinations and immunotherapy overall in ovarian cancer.

Neoadjuvant Chemotherapy Could Improve Outcomes in Ovarian Cancer

September 4th 2018

R. Wendel Naumann, MD, discusses the use of neoadjuvant chemotherapy and surgery for patients with ovarian cancer.

Dr. Herzog on Impact of Recent Clinical Trials in Ovarian Cancer

September 4th 2018

Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses the impact of recent clinical trials in ovarian cancer.

Dr. Coleman on Classifying Patients With Ovarian Cancer

August 31st 2018

Robert Coleman, MD, professor in the department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the classification of patients with ovarian cancer.

Dr. Brown on the Importance of Genetic Testing in Ovarian Cancer

August 30th 2018

Jubilee Brown, MD, professor of gynecologic oncology, Levine Cancer Institute, Carolinas HealthCare System, discusses the importance of genetic testing in patients with ovarian cancer.

Herzog Highlights History and Future of Frontline Ovarian Cancer Care

August 30th 2018

Thomas Herzog, MD, traces the therapeutic evolution of frontline treatment for patients with ovarian cancer.

Novel Agents, Genetic Testing Propel Personalized Care in Ovarian Cancer

August 29th 2018

Angeles Alvarez Secord, MD, discusses recent updates in ovarian cancer, with an emphasis on the clinical significance of genetic testing.

Dr. Herzog on Novel Therapies in Ovarian Cancer

August 27th 2018

Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses novel therapies in ovarian cancer.

Dr. Naumann on Neoadjuvant Chemotherapy in Patients With Ovarian Cancer

August 24th 2018

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses the use of neoadjuvant chemotherapy in patients with ovarian cancer.

Dr. Coleman on Immunotherapy in Ovarian Cancer

August 23rd 2018

Robert Coleman, MD, professor in the department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy in ovarian cancer.

Dr. Powell Discusses Immunotherapy in Ovarian Cancer

August 22nd 2018

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses immunotherapy in ovarian cancer.

Dr. Secord on Using Biomarkers to Guide Treatment Decisions in Ovarian Cancer

August 21st 2018

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses the use of biomarkers to guide treatment decisions in patients with ovarian cancer.

Dr. Herzog on the Optimal Use of Bevacizumab in Patients With Ovarian Cancer

August 21st 2018

Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses the optimal use of bevacizumab (Avastin) in patients with ovarian cancer.

Matulonis Highlights Niraparib, Immunotherapy Data in Ovarian Cancer

August 17th 2018

Ursula A. Matulonis, MD, highlights the activity and tolerability of niraparib and discusses other recent data in ovarian cancer.

Dr. Hardesty on Bevacizumab/PARP Inhibitor Combination in Ovarian Cancer

August 17th 2018

Melissa Hardesty, MD, gynecologic oncologist, Alaska Women’s Cancer Center, discusses the safety and efficacy of the bevacizumab/PARP inhibitor combination in ovarian cancer.

Patient-Experienced Toxicity Is a Biomarker Worth Considering

August 17th 2018

Maurie Markman, MD, says that the acceleration in regulatory agency approvals for novel antineoplastic agents and the focus of biomarker discovery proves that this is the era of precision medicine.

Novel Combination Shows Early Efficacy in Ovarian Cancer

August 16th 2018

David O'Malley, MD, discusses the emerging combination of mirvetuximab soravtansine plus bevacizumab and the evolving treatment landscape in ovarian cancer.

Dr. Turner on Important Steps for Genomic Profiling in Gynecologic Malignancies

August 14th 2018

Taylor Turner, MD, fellow, University of Alabama at Birmingham School of Medicine, discusses important steps to implement a genomic profiling program for gynecologic malignancies.